Haleon (HLN) Expected to Announce Earnings on Wednesday
by Renee Jackson · The Cerbat GemHaleon (NYSE:HLN – Get Free Report) will likely be releasing its Q1 2026 TU results before the market opens on Wednesday, April 29th. Analysts expect Haleon to post earnings of $0.2512 per share and revenue of $7.5713 billion for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 TU earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 4:00 AM ET.
Haleon (NYSE:HLN – Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The business had revenue of $3.65 billion for the quarter. On average, analysts expect Haleon to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Haleon Stock Down 0.9%
HLN stock opened at $9.50 on Tuesday. The company’s 50 day moving average price is $10.16 and its 200 day moving average price is $9.98. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. Haleon has a fifty-two week low of $8.71 and a fifty-two week high of $11.42. The firm has a market capitalization of $42.29 billion, a price-to-earnings ratio of 24.35, a PEG ratio of 2.03 and a beta of 0.26.
Haleon Dividend Announcement
The company also recently announced a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be paid a dividend of $0.1307 per share. This represents a dividend yield of 266.0%. The ex-dividend date is Friday, April 10th. Haleon’s dividend payout ratio is presently 64.10%.
Analysts Set New Price Targets
A number of analysts recently weighed in on HLN shares. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Argus upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Finally, HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Haleon currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.
Check Out Our Latest Stock Analysis on Haleon
Hedge Funds Weigh In On Haleon
Hedge funds have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust increased its stake in Haleon by 101.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock valued at $29,000 after purchasing an additional 1,433 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Haleon by 428.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock valued at $57,000 after purchasing an additional 5,124 shares during the last quarter. Cary Street Partners Financial LLC increased its stake in Haleon by 20.1% in the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock valued at $69,000 after purchasing an additional 1,113 shares during the last quarter. Finally, McMillan Office Inc. purchased a new position in Haleon in the fourth quarter valued at approximately $92,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.
Haleon Company Profile
Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.
The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.